PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

New programme shown to help dementia patients live independently

The neurodegenerative condition currently affects over 944,000 people in the UK.

A new programme led by Queen Mary University of London and funded by the Alzheimer’s Society has received positive trial results that could benefit carers and patients living with dementia.

The New Interventions for Independence in Dementia (NIDUS-Family) programme was successful in supporting patients and carers to achieve their goals compared to those who received usual care.

Affecting more than 944,000 people in the UK, dementia is a neurodegenerative disease that impairs a person’s ability to remember, think or make decisions on a daily basis.

Set up at University College London and now running at Queen Mary’s University London, NIDUS-Family aims to understand how to support carers who look after those with dementia at home.

Researchers tested the programme on a small number of participant pairs with over 300 people living with dementia and their unpaid carers.

The first stage of the programme involved discussing experiences with a facilitator who would set goals that focused on encouraging dementia patients to live independently at home.

These goals were then transformed into modules that participants could complete, including information and strategies to address specific needs such as exercise, activity and mobility.

The trial found that the programme was effective in enabling people to reach their goals regardless of the type or stage of dementia.

Moving forward with funding support from the National Institute for Health and Care Research, the NIDUS-Family team aims to implement the programme into health and social care practice.

Furthermore, additional research throughout the programme will be used to help address inequalities by investigating how the therapy can be rolled out exclusively, including adapting the programme for non-English-speaking UK populations.

Dr Richard Oakley, associate director, research and innovation, Alzheimer’s Society, said: “This is the first post-diagnostic support programme which can be delivered remotely and without clinical training, acting as a lifeline to thousands of carers across the UK.

“This will help to deliver the universal care and support people living with dementia desperately need.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026